||Robert A. Essner
Former Chairman & CEO Wyeth
Executive-in-Residence Columbia Business School
||Edward J. Ludwig ('75)
Chairman & CEO
BD (Becton Dickinson)
Robert A. Essner
Former Chairman & CEO, Wyeth
Retired Chairman of the Board, joined Wyeth in 1989 following thirteen
years with Sandoz Pharmaceuticals. In 1993 he became President of
Wyeth-Ayerst Laboratories responsible for the domestic pharmaceutical
business. In 1997, Mr. Essner was named President of
Wyeth-Ayerst Global Pharmaceuticals and assumed responsibility for the
global pharmaceutical business. The same year, he was elected
to the position of Executive Vice President and member of the Board of
Directors, Wyeth. In 2000, he was elected President and Chief
Operating Officer. Mr. Essner was elected Chief Executive
Officer in May 2001 and Chairman in January 2003.
A graduate of
Miami University, Oxford, Ohio, Mr. Essner received a
master’s degree from the University of Chicago.
Mr. Essner was Chairman of the Children’s Health Fund
Corporate Council for 13 years, and is presently on the
Fund’s Board of Directors. He is also as a member
of the Business Roundtable and Business Council. In addition,
he is a member of the Board of Directors of Massachusetts Mutual Life
Insurance Company and Lincoln Center for the Performing Arts.
Mr. Essner is past Chairman of the Pharmaceutical Research &
Manufacturers of America.
Mr. Essner lives
in New Jersey and New York with his wife, Anne, and their family.
Edward J. Ludwig ('75)
Chairman & CEO, BD (Becton Dickinson)
Edward J. Ludwig
serves as Chairman of the Board, President and Chief
Executive Officer of BD (Becton, Dickinson and Company), a global
medical technology company headquartered in Franklin Lakes, New
Jersey. Mr. Ludwig joined BD in 1979 as a senior financial
analyst and was named Chief Financial Officer in August 1995, President
in May 1999 and Chief Executive Officer in January 2000. He was elected
Chairman in February 2002.
Prior to joining BD, Mr. Ludwig served as a senior auditor with Coopers
and Lybrand (now Pricewaterhouse Coopers) and as a financial and
strategic analyst at Kidde, Inc.
Active in philanthropic efforts, Mr. Ludwig is a member of the Board of
Trustees of the College of the Holy Cross. He is a member and
past Chair of the Health Advisory Board for the Johns Hopkins Bloomberg
School of Public Health. He is also a trustee of the Hackensack (NJ)
University Medical Center. In March 2008, Mr. Ludwig ended a
2-year term as Chairman of the Advanced Medical Technology Association
(AdvaMed), the world’s largest medical technology
association. He currently serves on the AdvaMed Board of
Directors and chairs the Nominating and Governance Committee.
In the corporate arena, Mr. Ludwig serves on Aetna’s Board of
Directors and chairs the Audit Committee.
Mr. Ludwig graduated from The College of the Holy Cross with a B.A. in
Economics and Accounting and received his M.B.A. in Finance from
Columbia University. He is also a C.P.A.
and Biotech Panel
Director, Healthcare and Pharmaceutical Management Program
Adjunct Professor, Columbia Business School
25 years as a senior professional in the financial services and
healthcare/ pharmaceutical sectors. He was Managing Director
Merrill Lynch and JP Morgan in their global healthcare investment
banking groups, and Vice President, Corporate Planning &
Development at Merck & Co., Inc., with worldwide
for strategic planning and business development.
previous experiences also include the co-founding of American Health
Capital / VHA Enterprises, Inc., a healthcare/ financial services firm
serving the capital needs of multi-hospital systems and other
healthcare providers, and investment banking positions with Paine
Webber, Inc. and L.F. Rothschild, Unterberg, Towbin, Inc.
Director of the Healthcare and Pharmaceutical Management Program and
Adjunct Professor at Columbia University, Graduate School of Business.
He teaches two courses in
the spring semester: Strategy and Competition in
Pharmaceuticals and Biotechnology, and Healthcare
Investment and Dealmaking.
President and CEO, Novartis Oncology
David R. Epstein
is President & CEO, Novartis
this position, he is responsible for leading Novartis’ global
Oncology Business Unit, one of the world’s top Oncology
with seven key marketed products – Glivec, Femara, Zometa,
Sandostatin LAR, Exjade, Tasigna and Proleukin – and a
pipeline recognized as exceptionally broad and deep. In 2007, Novartis
Oncology’s sales grew 12.5% to $6.9bio and market share grew
Epstein currently oversees a staff of more than 5,000 employees
operating in over 50 countries. He is a member of Novartis
Pharma Committee and Pharmaceutical Executive Committee.
Epstein has held a series of positions of increasing responsibility
since joining the company as a new product manager with Sandoz in
1989. Epstein most recently served as CEO, Novartis Specialty
Medicines, overseeing the global Ophthalmics and Transplantation
Immunology Business Units in addition to his responsibilities leading
Novartis Oncology. He previously served as Chief Operating Officer of
Novartis Pharmaceuticals Corporation in the U.S and has held several
positions in marketing and general management. During the
planning process that resulted in the 1996 merger of Ciba-Geigy Ltd.
and Sandoz Ltd., Epstein co-chaired the U.S. and Canadian Pharma
Steering Committees as the Integration Officer, North
January 1997, he was promoted to Vice President, Marketing and Sales,
Specialty Business Sector, responsible for U.S. business units focused
on Oncology and Transplant/Immunology/Tissue Engineering.
to joining the company, he was an associate in the Strategy Practice of
consulting firm Booz, Allen and Hamilton.
Epstein holds a B. S. degree in Pharmacy with high honors from Rutgers
University College of Pharmacy and an M.B.A. in Finance and Marketing
from the Columbia University Graduate School of Business.
Kristin Peck ('99)
SVP Worldwide Strategy and Innovation, Pfizer
Kristin Peck is
President, Worldwide Strategy and Innovation for Pfizer Inc.
this role, Kristin is responsible for leading the team that develops,
enables and monitors the long term strategic plan for Pfizer in order
to drive profitable growth and deliver superior total shareholder
return as well as leading the company-wide efforts to accelerate
innovation and business model change.
Kristin’s team led the development of Pfizer’s
path forward launched in 2007 and a global operating model review in
2008. In the rapidly changing global healthcare environment,
Worldwide Strategy and Innovation is continuously focused on
identifying transformational business opportunities that extend and
enhance Pfizer’s existing capabilities and achieve
Kristin joined Pfizer in 2004 as Senior Director, Strategic Planning
and was appointed to the role of Chief of Staff to the Vice Chairman in
2006 with responsibility for aligning and coordinating strategies,
priorities and transformation activities across all groups in the
Office of the Vice Chairman. Kristin was promoted to Vice
President, Strategic Planning in 2007 before moving into her current
role in 2008.
Kristin is a member of the East Coast Executive Board for the Center
for Corporate Innovation and the Chief Strategy Officer
Roundtable. Kristin was a recipient of the 2005 Upjohn Award
her “Focus on Performance”.
Prior to joining Pfizer, Kristin was a Manager with the Boston
Consulting Group (BCG) for five years, focusing on strategy and
merger-related issues in the pharmaceutical and financial services
Before BCG, Kristin worked in private equity and real estate finance at
The Prudential, the O’Connor Group and J.P. Morgan.
holds a Bachelor’s degree from Georgetown University and an
from Columbia Business School. Kristin and her husband Bob
in Connecticut with their two young children and dogs.
VP, US Pharma Partnering and Alliance Management, Boehringer
Steve Marlin is
President, U.S. Pharma Partnering and Alliance Management for
Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Marlin began his career with Boehringer Ingelheim in 1987 in
R&D as a drug discovery researcher. After a 10 year
R&D which included increasing responsibilities as a researcher,
manager, and project leader, Dr. Marlin took a position in Business
Development, leading to his current position.
He received a Bachelor’s degree in Microbiology from DePauw
University, a Ph.D. in Cellular and Molecular Biology from The
University of Michigan, and was a Research Fellow at Harvard University
(Dana-Farber Cancer Institute).
VP, New Products, Forest Laboratories
Thomas Nee is
the Vice President, New Products, Marketing for Forest Laboratories,
Inc., based in New York. This team guides the commercial evaluation and
management of all potential products for Forest’s present and
future pipeline. The department is comprised of a number of talented
individuals who possess the business, scientific, and marketing acumen
necessary to form the market insights for Forest’s pipeline
acquisitions. Importantly, New Products at Forest is
constantly innovating in order to anticipate and envision the future
pharmaceutical market landscape.
Thomas joined Forest in 1990 and has held positions of increasing
responsibility in the marketing department. Over his career at Forest,
he has led product management groups in various therapeutic categories,
the marketing research group, and, most recently, created the New
Products group. His experience encompasses product and company
acquisitions, product launches, product lifecycle management, and
generic business management. Prior to joining Forest, he
worked in health care marketing at the Procter and Gamble Company,
Cincinnati. Thomas holds a Bachelor’s degree from
the University of Santa Clara and an MBA degree from Stanford
Vice President, Credit Suisse
is the lead US Biotech analyst at Credit Suisse where he covers both
large and small cap biotech companies. Prior to joining Credit Suisse,
Mr. Aberman covered small-cap biotech companies at Morgan Stanley.
Prior to moving to Wall Street, he was the director of Business
Development for Antigenics, a small cap biotech company.
Mr. Aberman received his medical degree from University of Toronto,
completed his residency in internal medicine at NewYork-Presbyterian
Hospital, and received his MBA from Wharton.
Devices and Diagnostics Panel:
Holly Sheffield ('97)
Managing Director, Credit Suisse
Holly is a
Managing Director and Global Head of the Medical Device Investment
Banking practice with 15 years of Healthcare Investment Banking
experience. She joined Credit Suisse following the merger
with Donaldson, Lufkin & Jenrette in 2000, joining DLJ in
1997. She is also co-chair of the Credit Suisse Investment
Banking Diversity Advisory Council. Holly received her MBA
from Columbia Business School and her BS from Cornell University.
Managing Director, Global
Head of Medical Devices, Goldman Sachs
Luke is global
head of the medical device investment banking
practice. He joined the firm’s Healthcare Group in
1999 and served as the group’s business unit manager in 2002.
named managing director in 2007. Prior to joining Goldman Sachs, Luke
was a consultant for McKinsey & Co. and a healthcare investment
banker at Credit Suisse First Boston.
Luke is vice chair of the Board of Directors of Literacy, Inc., a New
York City-based nonprofit focused on promoting early childhood
literacy. Luke received his MBA from Harvard Business School and his BA
in Anthropology, magna cum laude, from Harvard College.
Managing Director, Medical
Supplies and Devices, Leerink Swann
Swann in 2002 to focus on diversified medical supply and diagnostic
companies. Mr. Cranna was recently ranked #2 by the Wall Street Journal
in its 2008 “Best on the Street”
analysts’ survey and
earned a #1 ranking by the Financial Times in its 2008
“World’s Best Analysts” special report.
Mr. Cranna was Director and Senior Analyst in Equity Capital Markets at
ABN AMRO, where he was a Wall Street Journal All-Star in 2000 and 2004,
and a top-ten ranked analyst in the Reuters U.S. 2000 and 2001 Surveys.
Prior to ABN AMRO, Mr. Cranna served as Vice President, Equity Capital
Group at The Chicago Corporation. He also held the position of Senior
Consultant at the former Coopers & Lybrand for three years, in
company's Healthcare Financial Services Group. In addition, Mr. Cranna
served as Senior Analyst, Contract Financial Management Department of
Blue Cross and Blue Shield of Massachusetts.
Mr. Cranna received his
MBA in Finance, Cum Laude, from Northeastern University and his B.A. in
Economics, Cum Laude, from the University of Massachusetts, Amherst.
Director, Business Planning and
Cordis Corporation, a Johnson and Johnson Company
Corporation in April 2008 as the Director of Business Planning
Operations and has been with Johnson & Johnson since
During her time at J&J, Toshie has held roles of increasing
responsibility in both the Medical Device and Pharmaceutical segments
of the company. She began at Ethicon Women’s Health
Urology franchise where she held the position of Worldwide Finance
Director supporting the launch of five new products, the charter of six
R&D development projects. She helped to drive
growth in strategic umbrella markets and facilitated pricing
initiatives. As the Finance Director at Health Care Services,
Toshie supported the sales and marketing teams that called on Managed
Care Organizations, PBMs, GPOs and major hospital groups.
Toshie has over 17 years of professional experience in financial
analysis and strategic business planning. Prior to joining Johnson
& Johnson, Toshie spent most of her career in financial
where she worked in mergers and acquisitions and investor relations.
A graduate of the University of Pennsylvania with a degree in
Economics, Toshie also holds an MBA from The Kellogg School of
Management, Northwestern University.
Vice President, Research and Business Development, Medtronic
Dr. Krinke is
Vice President Business Development for Medtronic
Previously, he was Vice President Business Development and Executive
of Endogeny Bio Corporation. He also was Vice President Business
Strategic Planning at Celera Genomics. Dr. Krinke has over 10 years of
strategy expertise from two top management consulting firms: A.T.
Kearney, where he
was a Vice President, and McKinsey & Company.
Dr. Krinke completed his postdoctoral training as an American Cancer
Society Fellow at the California Institute of Technology. He holds a
Ph.D. in Molecular
Biology from the University at Albany and obtained his undergraduate
education at the
Technische Univeritaet Braunschweig in Germany. He is the recipient of
Rumbough Award for
Dedication to and Achievements in Diabetes research from the Juvenile
Diabetes Research Foundation International.
Cathy T. Doherty
Vice President, Hospital Services, Quest Diagnostics Incorporated
and Provider Panel
Linda V. Green, PhD
Armand G. Erpf Professor, Columbia Business School
Green is the
Armand G. Erpf Professor at Columbia Business School. She earned her
doctorate in Operations Research from Yale University. Her research,
which has focused on the development and application of mathematical
models of service systems, has resulted in dozens of publications in
the major technical journals including Operations Research,
Management Science, and The Journal of Applied
Probability as well as prominent healthcare journals such as Health
Services Research, Inquiry and Academic Emergency
early work led to the development of a model for the dispatching and
allocation of emergency vehicles which became the foundation for a
patrol car allocation model that is used by many major cities in the
U.S. as well as several other countries. Her current research is on
identifying operational policies to improve the delivery of healthcare.
Specific projects focus on improving emergency responsiveness,
developing strategies for the efficient and effective use of major
diagnostic equipment such as MRIs, providing timely access to primary
care, and the development of a new nurse staffing methodology. She is a
co-founder and co-director of the Columbia Alliance for Healthcare
Management, a unique partnership of the College of Physicians and
Surgeons, the Mailman School of Public Health and the Business School
of Columbia University dedicated to promoting interdisciplinary
research and education in healthcare management. She has been a
consultant for both private and public sector organizations and has
served on several advisory boards. She has served in many
administrative positions at both Columbia and in the major professional
societies and is currently the Department Editor for Public Sector
Applications for the journal Management
In recognition of her professional achievements, Professor Green was
elected a Fellow of INFORMS, the premier international professional
society for operations research and management science.
Alan Muney, MD
Executive Director, Private Equity, Blackstone Group; former CMO Oxford
Alan Muney is an
Director in the Corporate Private Equity group and the CEO of Equity
Healthcare, Blackstone's proprietary healthcare services group
purchasing organization. He is based in New York. Dr. Muney is involved
in portfolio management and monitoring of healthcare benefits.
Dr. Muney was the executive vice president and chief medical officer of
Oxford Health Plans and chief medical officer of United Healthcare of
the Northeast region from 1998-2007. Prior to that, he was senior vice
president and chief medical officer for Avanti Health systems, a
division of NYLCare health plans. He was also regional medical director
for Mullikin Medical Centers, a large multi-specialty medical group in
California. In these positions, Dr. Muney had responsibility for
business development, restructuring, utilization, quality and disease
management programs, employer health benefit design strategies, and
external relationships with providers, regulators, and the media. He is
a frequent lecturer on issues in managed health care.
received his BS in
Biology and his Doctor of Medicine degrees from Brown University, and a
Masters in Health Administration from the University of La Verne. He is
on the Board of Directors of Vanguard Health System and Team Health.
Assistant Professor of Public Policy,
John F Kennedy School of Government,
professor of public policy at the Harvard Kennedy School of Government.
He is a Faculty Research Fellow at the IZA Institute in Bonn, Germany,
and at the National Bureau of Economic Research (NBER) in Cambridge,
Massachusetts. His current research focuses on the role of medical
malpractice litigation on the delivery of health care, and the
economics of neonatal health and cardiovascular care, and technology
expenditure growth in healthcare. His research has
published in the American Economic Review,
the Journal of
Political Economy, the Journal of Labor
Economics, Journal of
Policy Analysis and Management, and Health Affairs. He is an
editor of the Journal of Human Resources, the American Economic Journal
and Economics Letters.
He has been a
at Dartmouth and MIT, and has been a consultant to the National Academy
of Science, the Robert Wood Johnson Foundation, and the RAND
Corporation. He is the recipient of an Outstanding Teacher Award, the
Arrow Award for the best paper in health economics, the Eugene Garfield
Award for economic research that impacts medicine, and is the
first-prize recipient of the Upjohn Institute's International
Dissertation Research Award.
Scott Collins, MD, MPH
Vice President, Quality
and Patient Safety, New York-Presbyterian Hospital
Dr. Karen Scott
Collins joined NewYork-Presbyterian Hospital in August
2007 as Vice President for Quality and Patient Safety. In this
position, she is responsible for developing and leading clinical
quality improvement and patient safety work across the five hospital
campuses of the Columbia and Cornell Medical Schools. Immediately prior
to this role, she served as Deputy Chief Medical Officer, New York City
Health and Hospitals. Prior to joining HHC, Dr. Collins was
Vice President at the Commonwealth Fund, responsible for developing the
Fund’s program on Quality of Care for Underserved
Dr. Collins has published articles and reports on trends and
experiences with managed care, women’s health, adolescent
health and minority health. She is the co-editor of two
books, Women’s Health: The Commonwealth Fund Survey, and
Minority Health in America, both published by Johns Hopkins University
Press. In April 2002, Dr. Collins received the Healthcare
Hero Award from the Congressional Black Caucus.
Dr. Collins graduated from Harvard University with a degree in History
of Science. She received her Doctor of Medicine from Cornell
University Medical College and an M.P.H. from the Bloomberg School of
Public Health at Johns Hopkins University.
Vice President, Senior Market Development, Medco Health
Andrew Davis is
Vice President, Senior Market Development at Medco Health
Solutions. Mr. Davis is accountable for Medco’s
national Prescription Drug Plan for individuals and employer groups,
developing and executing Medco's insured product growth strategy and
distribution development and management plan for retirees and Medicare
beneficiaries across multiple markets and group/individual solutions.
Prior to assuming this role, Mr. Davis oversaw the national account
business for UnitedHealth Group, a large managed care client supported
by Medco. Prior to joining Medco in 2000, Mr. Davis was with Blue Cross
Blue Shield of Minnesota, the Minnesota Department of Health and Human
Services, and also worked on Capitol Hill for U.S. Representative James
Partner and Managing Director, Boston Consulting Group
Jon Kaplan is a
Partner and Managing Director for The Boston Consulting Group. Mr.
Kaplan joined BCG's Chicago office in 2007 and is a core member of BCG
's Health Care and Strategy Practice Areas. Mr. Kaplan has
been serving the health care industry for more than 20 years.
Prior to joining the firm, Mr. Kaplan was a Senior Partner for the
firms of Accenture and Ernst & Young, focusing on all
components of the health care industry.
Mr. Kaplan has assisted global health care clients in the payer,
provider, diagnostic, imaging, equipment, Rx, solution and distribution
fields, focusing on areas of competitive strategy, mergers &
acquisitions, strategic planning and marketing, services development,
operations improvement, technology architecture and planning, and
Mr. Kaplan graduated from Cornell University with an AB in
economics. He received his MBA from the Executive Program of
Northwestern University's J.L.Kellogg Graduate School of Management,
and holds an MPH in biostatistics from the University of
Pittsburgh. He has served on average over ten years on the
Boards of Juvenile Diabetes Research Foundation, Arthritis Foundation
and Junior Achievement.
and Acquisitions Panel
SVP, Head of Mergers and Restructurings Group, Booz and Company
Gerald Adolph is
a New York-based Senior Partner with Booz & Company with a
specialty in strategy and operations for technology-driven businesses.
Mr. Adolph's work primarily focuses on assisting clients with growth
strategy, new business development, and industry restructuring. In
support of his clients' growth agendas, Mr. Adolph has led M&A
pre-deal assessments as well as multiple complex, challenging
post-merger integration assignments.
Mr. Adolph is a former member of the firm’s Board of
Directors, a past leader of the firm’s global chemicals
business, and a former leader of the firm’s global consumer
and health work. He currently leads Booz & Company’s
work for mergers and restructuring clients.
Mr. Adolph has
received Booz & Company's Professional
Excellence Award in recognition of his outstanding and innovative
client service for Quest Diagnostics. A thought leader in his
field, he has also contributed articles to Strategy+Business, The Deal,
Corporate, and CFO Magazine.
Mr. Adolph graduated from MIT with a BS in chemical engineering and
management science/organizational psychology as well as a
degree in chemical engineering. He received his MBA from
Harvard Business School.
Managing Director, Head of Healthcare Investment Banking, Goldman Sachs
Ken Hitchner is head of Goldman Sach’s healthcare banking
group. He joined the firm in 1992 as a member of the Corporate Finance
Department. In 1995, Mr. Hitchner joined the healthcare group as a
founding member. He became head of Goldman Sachs' global medical device
banking practice in 1998 and the global pharmaceutical banking practice
in 2001. Some of Mr. Hitchner’s current clients are Johnson
& Johnson, Medtronic, Eli Lilly and GE Healthcare among others.
He was named managing director in 2000 and partner in 2002.
Prior to joining the firm, Mr. Hitchner was a lieutenant commander and
naval aviator in the US Navy. He is a trustee and member of the Board
of Meridian Health Systems, Monmouth University and The Rumson Country
Day School. Mr. Hithchner graduated from the University of Colorado and
received an MBA as a merit fellow at Columbia Business School.
Director, Head of Heathcare Investment Banking, JP Morgan Chase
Huffines joined J.P. Morgan in 1992 and is currently co-head of the
global healthcare investment banking group. Mr. Huffines is
primarily focused on medical device, pharmaceutical, and biotechnology
clients. Mr. Huffines has advised numerous healthcare
companies on strategic transactions, including in 2008: Celgene's
acquisition of Pharmion, Kinetic Concept's acquisition of LifeCell,
Amgen's sale of Amgen K.K. to Takeda, Eisai's acquisition of MGI
Pharmaceuticals, Takeda on its division and integration of the Takeda
Abbott Products joint venture, Sirtis Pharmaceutical's sale to Glaxo
Prior to joining J.P. Morgan, Mr. Huffines worked
at Alex Brown & Sons, specializing in equity financings and
advisory assignments for emerging growth companies.
Huffines has an MBA degree from the University of Virginia, where he
received the faculty award for academic excellence. He has a
B.A. degree from the University of North Carolina, where he majored in
English and Economics.
Mr. Huffines is married and has four
children. His volunteer work includes The Brookings/Gates
Global Health Innovative Financing Advisory Group, the Student Spponsor
Partnership, and serving as a board member of the Spence School.
Stuart Smith ('84)
Managing Director, Head of Heathcare Investment Banking, Credit Suisse
Stuart F. Smith
is a Managing Director of Credit Suisse and Head of Health Care within
the Investment Banking Department, based in New York.
Prior to joining Credit Suisse First Boston in 1999, Mr. Smith was a
Managing Director of Alex Brown & Sons and its successor firms.
He has been involved in structuring numerous M&A transactions
as well as effecting financings for clients across all sectors of the
health care industry including: Express Scripts, Genzyme, IDX, King
Pharmaceuticals and Lab Corp.
Mr. Smith graduated from Franklin and Marshall College and received a
J.D. from the University of Connecticut School of Law and an MBA from
Global Head of Business Development, Daiichi Sankyo
Van Duyne joined Daiichi Sankyo in 2003. In his current
position, he chairs the Senior Licensing Committee and works directly
with senior management, in Tokyo and the US and Europe, on key
licensing and business development projects.
Prior to this role, Mr. Van Duyne was Senior Vice President of
Corporate Development at Pharmacia Corporation, serving in that
capacity until Pharmacia was acquired by Pfizer in 2003.
Prior to Pharmacia, Mr. Van Duyne was, for a brief time, co-founder of
MedPointe, a specialty pharmaceutical company. Previously, he
was Vice President Licensing & Business Development at
Warner-Lambert Company, where he worked for seventeen years until the
company was acquired by Pfizer in 2000.
Mr. Van Duyne graduated from the University of Pennsylvania with a BS
Economics degree. He received his MBA from Wharton his J.D. from
Sciences Ventures Panel
Barbara Dalton, PhD
VP, Venture Capital, Pfizer
Vice President of Venture Capital for
Pfizer Inc. She
joined the company in
2007 with responsibility for growing Pfizer’s corporate
in her career, Ms.
Dalton pursued drug discovery research at SmithKline’s
laboratories and joined
their venture capital group in the early 1990’s. While there,
Partners, a private New York based venture capital firm (SmithKline was
leading limited partner), and joined the firm in 2003.
Ms. Dalton has
managed over 20 fund investments and 60
diverse company investments in the US and Europe and has had direct
responsibility for biotechnology therapeutic and platform technology
as well as healthcare IT and service businesses.
graduated from Pennsylvania State University and
received a PhD from The Medical College of Pennsylvania, where she
trained as a
research scientist in virology. She
currently serves on the Board of Directors for the Penn State Research
and is advisor to the Dean of the Eberly College of Science.
Dalton also serves on the board of the New York
Biotech Association, NYSTAR, NYCIF and the National Venture Capital
Executive Director, New Ventures, Eli Lilly and Company
leads the New Ventures Division of Eli Lilly and Company
which includes Lilly Ventures where he is the Senior Managing Director.
Carroll is the founder of Lilly Asian Ventures, the first venture
capital group of its kind in the pharmaceutical industry.
to assuming his current role, Mr. Carroll was the founding chief
executive officer of InnoCentive, Inc., the first e-business venture
created by Lilly. Among other positions Mr. Carroll has held
Lilly, he was the U.S. attorney for Prozac®.
Mr. Carroll has also served as senior vice president of RealMed, a
venture-backed company based in Indianapolis, which created the first
real-time health claims adjudication system. Earlier in his
career, he practiced law with a large private law firm in New York and
negotiated technology transactions for General Electric Company.
His education includes a J.D. degree from Syracuse University College
of Law. He also holds a bachelor's from Syracuse University
Beta Kappa) and a masters of public administration degree from the
Maxwell School of Syracuse, where he is a member of the Board of
Advisors. He is also a member of the Board of Directors for
Ventures and Lilly Asian Ventures portfolio companies including Citic
Pharmaceuticals, Hydra Biosciences, InnoCentive and GlobeImmune, and is
chairman of the advisory board for the Indiana Future Fund.
Managing Director, New Leaf Venture Partners
Ron Hunt is a
Managing Director at New
Leaf Venture Partners, and focuses on investments in biopharmaceuticals
and laboratory infrastructure companies. Ron joined the Sprout
healthcare team in January 1998, and was part of the team that spun out
of the Sprout Group (the venture capital affiliate of Credit-Suisse) in
2005 to form NLV.
Prior to joining Sprout, Ron was a consultant with
Coopers & Lybrand Consulting and then with The Health Care
Group (a division of the Interpublic Group of companies) for a combined
4 years. His consulting work focused on strategic and operational
engagements for clients in the pharmaceutical and medical device
Prior to entering the consulting field, Ron held a number
of sales and marketing positions for a combined 8 years with Johnson
& Johnson and SmithKline Beecham Pharmaceuticals. Ron is a
graduate of The Wharton School (MBA) and Cornell University (BS). Ron
was the lead investor and served on the boards of Cerexa, Inc. and
Aspreva Pharmaceuticals up until their recent acquisitions by Forest
Laboratories and Gallenica Group, respectively. Ron has served on a
number of other boards for companies in a broad range of healthcare
sectors including biotech, laboratory services, health care information
technology, and laboratory instrumentation.
Timothy Howe ('85)
Partner, CHL Medical Ventures
Tim has been
investing in private equity since joining Schroder
Ventures in 1984. He has been an active investor and board member
responsible for numerous venture investments in the biotechnology,
medical device and healthcare services areas, including Innotech, Inc.
(acquired by Johnson & Johnson), Camitro Corporation (acquired
by ArQule, Inc.), and Alexion Pharmaceuticals, Inc.
Tim also played a leading role in the formation of Biotechnology
Investment Group, L.L.C., which took over a portfolio of equity
investments in many financially distressed biotechnology companies. Tim
was instrumental in working with these portfolio companies in arranging
financings, mergers, and ultimate successful realizations.
Tim has been a director of nineteen companies and is currently on the
boards of Bionaut Pharmaceuticals, Inc., Comprehensive NeuroScience,
Inc., Medicus Insurance Holdings, Inc. and MedMark Services, Inc. He is
also an Adjunct Assistant Professor at Columbia Graduate School of
Business teaching venture capital management. Tim is a graduate of
Columbia College and the Columbia Graduate School of Business.
Managing Director, Symphony Capital
co-founded Symphony in 2002
and has more than 25 years of experience advising investors and
management teams of pharmaceutical, biotechnology and related
healthcare companies. Prior to joining Symphony, he was a
Managing Director and co-founder of Wilkerson Partners, a healthcare
and life sciences strategy consulting firm.
Taranto was a co-founder and partner, for 17 years, with The Wilkerson
Group and its successor, TWG/IBM Healthcare Consulting, where he was
head of the Global Pharmaceutical practice. Throughout his
TWG/IBM career, he was instrumental in shaping strategy and investment
opportunities for leading biopharmaceutical companies and private
equity investors. His clients have included industry leaders
and emerging growth-stage companies, as well as private equity
investment firms. Prior to joining TWG, Mr. Taranto was a
consultant with McKinsey & Company from 1980 to 1983.
He earned an M.B.A. in Finance from Columbia University and received
his B.S. in Electrical Engineering from Yale
University. Mr. Taranto is a director and Chairman of
Symphony Evolution, Inc. and Symphony Dynamo, Inc., and a director of
Symphony Allegro, Inc., all Symphony portfolio companies. In
addition, Mr. Taranto serves on the Business Council of Solera Capital
LLC, the Board of Directors of MIQS, Inc. and the Advisory Board of
Doctors of the World-USA.
Joseph Gulfo, MD
President and CEO, Director,
Electro-Optical Sciences, Inc.
V. Gulfo, M.D., M.B.A. has
served as President and Chief Executive Officer and a member of
Electro-Optical Sciences board of directors since January 2004. From
May 1999 to November 2004, he served as Chairman, Chief Executive
Officer and President of Antigen Express, Inc., a development-stage
company developing immunodiagnostics and therapeutics for cancer.
Previously, he was Chief Operating Officer and a Director of Anthra
Pharmaceuticals, Inc. and Chairman of that company's UK subsidiary.
Dr. Gulfo serves as a director of ProCertus BioPharm, Inc., a
privately-held company. Dr. Gulfo received a B.S. in Biology from Seton
Hall University, an M.D. from the University of Medicine and Dentistry
of New Jersey and an M.B.A. in Finance from Seton Hall University.
Frank R. Lichtenberg, PhD
Courtney C. Brown Professor of Business
Columbia Universtiy Graduate School of Business
Lichtenberg is Courtney C. Brown Professor of Business at the Columbia
University Graduate School of Business, and a Research Associate of the
National Bureau of Economic Research. He received a BA with
Honors in History from the University of Chicago and an MA and PhD in
Economics from the University of Pennsylvania.
Professor Lichtenberg previously taught at Harvard University and the
University of Pennsylvania. He has served as an expert for
the Federal Trade Commission, the U.S. Dept. of Justice, and state
Attorneys General, and has testified before Congress. He has
worked for several U.S. government agencies, including the Department
of Justice, the Congressional Budget Office, and the Census Bureau, and
been a visiting scholar at the Wissenschaftszentrum Berlin, the
University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the
introduction of new technology arising from research and development
affects the productivity of companies, industries and nations. Recently
he has performed studies of the impact of pharmaceutical innovation on
longevity, the effect of computers on productivity in business and
government organizations, and the consequences of takeovers and
leveraged buyouts for efficiency and employment. His articles
have been published in numerous scholarly journals and in the popular
press. His book Corporate Takeovers and Productivity has been
published by MIT Press. He was awarded the 1998 Schumpeter
Prize for his paper, Pharmaceutical Innovation as a Process of Creative
Destruction, and a 2003 Milken Institute Award for Distinguished
Economic Research for the paper, Pharmaceutical Knowledge-Capital
Accumulation and Longevity.
He has been awarded research fellowships, grants, and contracts by the
National Science Foundation, the National Institute of Standards and
Technology, Merck and Co., the Fulbright Commission, the Brookings
Institution, the Alfred P. Sloan Foundation, The German Marshall Fund,
the American Enterprise Institute, and other organizations.
He has served as a consultant to private organizations and government
agencies including the Securities Industry Association, Pfizer, Inc.,
the Community Preservation Corporation, the RAND Corporation, the New
York City Water Board, Touche Ross and Co., The Walt Disney Company,
McGraw-Hill, and the National Pharmaceutical Council. He is an
Affiliate of the economics consulting firm LECG, LLC.
Partner, Deloitte Consulting
Sanjay Behl is a
Principal in the Strategy & Operations practice at Deloitte
Consulting. Mr. Behl brings over ten years of experience in consulting
for global pharmaceutical companies on a range of business issues, from
manufacturing and supply chain optimization to revenue enhancement to
organizational redesign. Before coming to Deloitte, Mr. Behl
was involved with development in the chemical industry, first as a
Senior Development Engineer at Engelhard Corporation and then as
Business Development Manager at Cabot Corporation, both chemical
companies with global operations.
Mr. Behl has been issued 12 US patents and has published 19
international journal articles as well as five book chapters. He has
also been a thought leader at Deloitte on “Sales Force
Productivity and Effectiveness” in a pharmaceutical company
and “Future of Mergers and Acquisition Strategy” in
the pharmaceutical industry.
Mr. Behl graduated the Indian Institute of Technology with a B.Tech
before pursuing an M.S. in Chemical Engineering at Syracuse
University. He went on to receive a Ph.D. in Materials
Science and Engineering at the University of Florida and also earned an
MBA from INSEAD.
Daulaire, MD, MPH
President and CEO, Global Health Council
Daulaire is president and CEO of
the Global Health Council,
the world’s largest membership alliance of public health
professionals and organizations working in over 100 low-income
countries, and dedicated to raising the attention, resources, and
knowledge needed to improve health worldwide. He served in
1990s as USAID’s Deputy Assistant Administrator for Policy
was the U.S. government’s Senior International Health Policy
Advisor, serving as negotiator at numerous international
Previously he worked for two decades on
and managing maternal and child health services in developing
countries, and on field research to identify and validate effective and
high-impact health interventions to reduce child
Phi Beta Kappa and summa cum laude graduate of Harvard College, he
received his M.D. from Harvard Medical School and his
Public Health from Johns Hopkins University. He is a member
the National Academy of Science’s prestigious Institute of
Medicine, testifies frequently before Congress, and has appeared widely
in the national and international media on global health issues.
Partner, Bain & Company
is a partner in Bain’s Healthcare Group, based in Chicago.
Prior to joining Bain in 2008, Andy was a partner in the Health
Sciences Practice at Oliver Wyman, a global management consultancy.
During his 10+ years at Oliver Wyman (formerly named Mercer
Management Consulting), Andy served clients in the pharmaceuticals and
biotechnology arena, and also conducted work in the global health space
with organizations such as the Bill & Melinda Gates Foundation,
UNICEF and the GAVI Alliance. Andy has conducted extensive strategy
work for both private sector and public sector clients to address
issues for life-saving pharmaceutical products in emerging markets and
the developing world. Andy has particular expertise in the areas of
vaccines and infectious diseases, in which he is an internationally
recognized strategy consultant.
Prior to joining Oliver Wyman, Andy worked in the Corporate Finace
Group of J.P. Morgan Securities. Andy earned an M.B.A. from the
University of Chicago Graduate School of Business, and a B.A. in
Economics from Northwestern University. He resides in the Chicago area
with his wife Susan and his three children.
Senior Director, Strategy Development & Realization
Merck Vaccines and Infectious Diseases
is the Senior
Director of Strategy Development and Realization for Merck's global
vaccine and infectious diseases business. He is responsible
developing strategies that cut across Merck's pediatric, adolescent and
adult vaccine and infectious disease franchises, which include brands
such as Gardasil®, RotaTeq®, Zostavax®,
Isentress®. Eric's current area of focus is on
Merck's approach for vaccines and infectious disease products in
emerging or under-penetrated markets, including China, India, Brazil,
Korea, Russia, Turkey and Poland.
Eric joined Merck in 1989 as part of the Merck Manufacturing Division
and has spent the last 12 years in positions of increasing
responsibility in sales, market research and marketing, working on such
brands as Singulair®, Fosamax®, and Propecia®.
Eric is the recipient of numerous sales, marketing and leadership
awards including the Vice President's Club Sales Award and Marketer of
Eric holds a Bachelor of Science Degree in Mechanical Engineering from
the University of Connecticut and a Masters of Business Administration
from Rutgers Graduate School of Management.
Eric lives in Pennsylvania with his wife and their 2 sons. In
spare time he trains and competes in endurance events and has completed
multiple marathons, triathlons and charity bike tours.
N. Sampat, PhD
Assistant Professor, Columbia University
PhD, is an assistant professor in the Department of
Health Policy and Management and (by courtesy) in the School of
International and Public Affairs at Columbia University. An economist
by training, Sampat is centrally interested in issues at the
intersection of health policy and innovation policy. His current
projects examine the impacts of new global patent laws on innovation
and access to medicines in developing countries, the political economy
of the National Institutes of Health, the roles of the public and
private sectors in pharmaceutical innovation, and institutional aspects
of patent systems. Dr. Sampat has also written extensively on the
effects of university patenting and "entrepreneurship" on academic
medicine, and is actively involved in policy debates related to these
Dr. Sampat was previously an Assistant Professor at the School of
Public Policy at Georgia Tech, and a Robert Wood Johnson Foundation
Scholar in Health Policy Research at the University of Michigan." He is
recipient of a Robert Wood Johnson Foundation "Investigator Award" to
study how the NIH allocates its funds across disease areas. He is also
principal investigator on a Ford Foundation initiative examining patent
policy in developing countries, and director of the Columbia-Stanford
Consortium on biomedical innovation.
Assistant Dean & Managing Director, Career Management Center
Columbia Universtiy Graduate School of Business
Gina joined the
administration at Columbia Business School in 1996, in 1999 was named
Assistant Dean & Director of the Office of MBA Career Services
and Managing Director in 2005. The Office, renamed the Career
Management Center in 2007, serves over 1400 full-time MBAs and 600
Executive MBAs, maintains a career management library and related
student and recruiter web sites, offers one-on-one and group advising
sessions and presents a wide variety of career management workshops.
For 14 years, the Office has organized and hosted the Chazen
MBA Career Services Conference, addressing the key issues faced by
international MBA career advisors.
As Managing Director, Gina oversees a team of employer relations
specialists and career education and advising professionals. She both
counsels students in all aspects of career development and the job
search and works with corporations and other MBA hiring organizations
to help them develop recruiting strategies. Gina and her team conduct
extensive outreach efforts to encourage additional companies to recruit
Columbia Business School students. Gina speaks frequently at various
educational and corporate recruiting conferences. She was a 1998
recipient of The Robert W. Lear Award for extraordinary commitment to
the student body.
Prior to coming to Columbia, Gina was a Partner at the advertising and
communications firm Bozell Worldwide. During her 12 years at the firm,
she worked with a variety of clients including Avis, Pfizer, Merrill
Lynch and Joseph E. Seagram & Sons. Her initial assignment in
advertising was on the Procter & Gamble account at Saatchi
& Saatchi. Directly out of college, Gina was a research
assistant for economic advisors to President Carter.
Managing Director, Biotechnology & Pharmaceuticals, Korn/Ferry
Director, Biotechnology & Pharmaceuticals for
North American Healthcare Practice. His practice group includes a team
of industry experienced consultants who serve the unique recruiting
needs of biotechnology, pharmaceutical and life sciences companies at
all stages of development.
Having successfully conducted hundreds of executive recruiting
assignments in the life sciences, Mr. Israel is an acknowledged
industry expert and consultant to venture-backed start-ups, emerging
growth companies and global pharmaceutical companies. He has recruited
many chief executive officers, heads of research and development and
general management of all functions.
Prior to returning to Korn/Ferry, where he established the life
sciences practice, Mr. Israel served as Chief Administrative Officer
for Cytel Corporation, a biopharmaceutical company in San Diego. Mr.
Israel is originally from North Carolina and holds a Bachelor of Arts
Degree from the University of North Carolina at Chapel Hill.
Partner and Managing Director, Financial Services, Boyden Global
Lipstein is Partner and Managing Director in Boyden Global Executive
Search’s Financial Services Practice.
A veteran search professional with twenty years of experience, Mr.
Lipstein previously spent almost a decade in the corporate sector and
on Wall Street.
As a member of the global Financial Services practice, Mr. Lipstein is
well recognized for his record of achievement placing professionals in
a broad range of functional and product areas.
Prior to becoming an Executive Search Consultant, Mr. Lipstein was a
financial executive with the American Broadcasting Companies and an
investment banker at the media industry M&A boutique Henry
He is a graduate of the City University of New York (Brooklyn College;
BA, Economics) and received an MBA with Distinction from Pace
University Lubin School of Business.
Mr. Lipstein is currently Chairman of the Career Development Committee
of the New York Society of Security Analysts (NYSSA). He
received a Volunteer of the Year Award for his contribution to this
11,000+ professional organization. He has produced and
numerous NYSSA seminars on current events and relevant trends in the
Mr. Lipstein is regularly quoted in the media, including, among others,
The Wall Street Journal, Business Week, Institutional Investor,
Bloomberg, and Investment Dealers Digest.
SVP, Human Resources, Wyeth
is Senior Vice President, Human Resources, Wyeth. In this
role, she has responsibility for Wyeth's global human resources
function, which includes human resources policies; employee pay and
benefits programs; labor relations and employment matters; leadership
development and training; employee diversity programs; talent
management planning and executive recruitment.
Ms. Peppard is a member of the Wyeth Management Committee, the Human
Resources and Benefits Committee, Law/Regulatory Review Committee and
Operations Committee. She also leads the HR Management
Committee. Ms. Peppard has focused her efforts on
facilitating change in the business and redefining the role of Human
Resources in Wyeth through an increased business orientation and
Ms. Peppard joined Wyeth-Ayerst (now Wyeth Pharmaceuticals) in 1999.
Prior to joining the Company, she worked as Senior Director,
Organization Development and Training at Parke-Davis in Ann Arbor,
Michigan and as Vice President of Human Resources at Cyto Therapeutics,
a small biotechnology company in Rhode Island. In addition,
she has worked as an internal consultant in the computer and financial
Ms. Peppard received her MBA from the University of Michigan with a
dual concentration in Organizational Behavior and Finance.
Head of North America Recruiting, Booz and Company
Gustavo Alba is
a Director with Booz
Company and leads their recruiting activities. In this role,
is responsible for both experienced and campus hiring
He is based in New York.
During his tenure at Booz & Company, Gustavo developed the
America experienced hire channel and facilitated a rapid scale up of
Booz & Company’s European offices.
successfully led the global recruiting activities for an entirely new
career model called Design. Prior to joining Booz &
Gustavo was responsible for building a full service global recruiting
function at Neoris, a division of Cemex.
Gustavo has more than 10 years experience leading human capital
initiatives focused on talent acquisition strategies and building world
class recruitment organizations. He has developed an
within the professional services market.
VP, Talent Management and Acquisition, Pfizer
Pfizer in July 2008 as Vice President of Talent Management and
Acquisition with responsibility for creating greater business value
through talent by driving world-class talent management and acquisition
processes to insure Pfizer is able to attract, retain and develop key
talent. She joins the Worldwide Talent and Organization Capability team
(WTOC) which collectively is focused on building the capability of the
Pfizer organization to be high-performing and adaptive by developing
leaders, managers and colleagues with the capabilities needed to
deliver business results now and in the future AND enabling an
organization culture that unleashes these capabilities.
professional with 15 years of experience driving organizational change
across varied industries and diverse organizational cultures and
functions. Examples of her areas of expertise include: Talent
Management, Leadership and Organizational Development, Strategic
Planning and Execution, and Competency Profiling among others.
Wendy was Executive Director of Leadership Development at Novartis
Pharmaceuticals Corporation and was responsible for Leadership
Development, Talent Management and Organizational
She spent 7 ½ years in various HR roles at Novartis and
support to the Development, Sales, Marketing, IT and Finance
functions. Prior to Novartis, Wendy was leading OD and Talent
Management initiatives in support of the CMO of AlliedSignal/Honeywell
to develop marketing capabilities necessary to drive growth.
has also provided internal consulting services to Phillip Morris USA,
Liz Claiborne, and Arthur Andersen. Wendy earned a Bachelor of Arts in
Social Relations from Lehigh University, a Masters of Arts in College
Student Personnel and Masters in Organizational Development from
Bowling Green State University.
time, Wendy likes to ski, travel, and spend time with her nieces and